Donna L Johnston1, Lillian Sung2, Daniel Stark3, A Lindsay Frazier4, Abby R Rosenberg5,6,7. 1. Division of Paediatric Haematology/Oncology, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, ON, K1H 8L1, Canada. djohnston@cheo.on.ca. 2. Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada. 3. Section of Oncology and Cancer Research, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK. 4. Division of Childhood Cancer and Blood Disorders, Dana-Farber/Children's Hospital, Boston, USA. 5. Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, USA. 6. Division of Hematology/Oncology, Department of Pediatrics, University of Washington School of Medicine, Seattle, USA. 7. Fred Hutchinson Cancer Research Center, Seattle, USA.
Abstract
PURPOSE: Peripheral neuropathy is an important, yet poorly studied, side effect of pediatric cancer treatment. There are many measures of patient-reported peripheral neuropathy in adults but very few in children. We aimed to systematically review and summarize reliable and valid patient-reported peripheral neuropathy scales used in pediatrics. METHODS: Four major electronic databases (Medline, Embase, EBSCO Host in Cumulative Index to Nursing and Allied Health Literature, and PsycINFO) were reviewed for studies that measured peripheral neuropathy in pediatric patients. Studies eligible for inclusion were those that described use of any patient-reported scale of peripheral neuropathy among children, adolescents, and young adults with any underlying diagnosis (not limited to cancer). RESULTS: From a total of 765 articles retrieved, 5 met eligibility criteria and were included. One was a neuropathy symptom score used in patients with diabetes, and the remaining four were in oncology patients and all were based on the total neuropathy score. All involved objective assessments conducted by trained professionals; none relied purely on patient report. CONCLUSIONS: There are no validated instruments that consist solely of a patient-reported outcome measure of neuropathy in pediatrics and adolescents. Because the clinical evaluation of neuropathy requires specialized training, it is not generalizable in large studies conducted in many diverse institutions. Future studies should validate adult patient-reported neuropathy scales in pediatric and adolescent populations, or develop novel instruments designed for this population.
PURPOSE:Peripheral neuropathy is an important, yet poorly studied, side effect of pediatric cancer treatment. There are many measures of patient-reported peripheral neuropathy in adults but very few in children. We aimed to systematically review and summarize reliable and valid patient-reported peripheral neuropathy scales used in pediatrics. METHODS: Four major electronic databases (Medline, Embase, EBSCO Host in Cumulative Index to Nursing and Allied Health Literature, and PsycINFO) were reviewed for studies that measured peripheral neuropathy in pediatric patients. Studies eligible for inclusion were those that described use of any patient-reported scale of peripheral neuropathy among children, adolescents, and young adults with any underlying diagnosis (not limited to cancer). RESULTS: From a total of 765 articles retrieved, 5 met eligibility criteria and were included. One was a neuropathy symptom score used in patients with diabetes, and the remaining four were in oncology patients and all were based on the total neuropathy score. All involved objective assessments conducted by trained professionals; none relied purely on patient report. CONCLUSIONS: There are no validated instruments that consist solely of a patient-reported outcome measure of neuropathy in pediatrics and adolescents. Because the clinical evaluation of neuropathy requires specialized training, it is not generalizable in large studies conducted in many diverse institutions. Future studies should validate adult patient-reported neuropathy scales in pediatric and adolescent populations, or develop novel instruments designed for this population.
Authors: Daniela Matei; Anna M Miller; Patrick Monahan; David Gershenson; Qianqian Zhao; David Cella; Victoria L Champion; Stephen D Williams Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison Journal: N Engl J Med Date: 2006-10-12 Impact factor: 176.079
Authors: Marianne Brydøy; Jan Oldenburg; Olbjørn Klepp; Roy M Bremnes; Erik A Wist; Tore Wentzel-Larsen; Erik R Hauge; Olav Dahl; Sophie D Fosså Journal: J Natl Cancer Inst Date: 2009-12-16 Impact factor: 13.506
Authors: Rachel M Taylor; Lorna A Fern; Anita Solanki; Louise Hooker; Anna Carluccio; Julia Pye; David Jeans; Tom Frere-Smith; Faith Gibson; Julie Barber; Rosalind Raine; Dan Stark; Richard Feltbower; Susie Pearce; Jeremy S Whelan Journal: Health Qual Life Outcomes Date: 2015-07-28 Impact factor: 3.186
Authors: Ellen M Lavoie Smith; Clare Kuisell; Grace A Kanzawa-Lee; Celia M Bridges; Paola Alberti; Guido Cavaletti; Rima Saad; Susanna Park Journal: Lancet Haematol Date: 2020-05 Impact factor: 18.959
Authors: Samah Hayek; Rikeenkumar Dhaduk; Yadav Sapkota; William E Evans; Barthelemy Diouf; Kari Bjornard; Carmen L Wilson; Melissa M Hudson; Leslie L Robison; Raja B Khan; Deo Kumar Srivastava; Kevin R Krull; Kirsten K Ness Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-09-28 Impact factor: 4.090
Authors: Philippe Bérubé-Mercier; Diane Tapp; Marie-Ève Cimon; Tiffany Li; Susanna B Park; Éve Bouhêlier; Kaitlin McGarragle; Lye-Ann Robichaud; Jennifer S Gewandter; Maxime Bouchard; Lynn R Gauthier Journal: BMJ Open Date: 2022-04-06 Impact factor: 2.692
Authors: Ross J Lordon; Sean P Mikles; Laura Kneale; Heather L Evans; Sean A Munson; Uba Backonja; William B Lober Journal: Health Informatics J Date: 2020-06-20 Impact factor: 2.681